6,433 reports of this reaction
1.9% of all USTEKINUMAB reports
#5 most reported adverse reaction
PSORIASIS is the #5 most commonly reported adverse reaction for USTEKINUMAB, manufactured by Janssen Biotech, Inc.. There are 6,433 FDA adverse event reports linking USTEKINUMAB to PSORIASIS. This represents approximately 1.9% of all 346,490 adverse event reports for this drug.
USTEKINUMAB has an overall safety score of 78 out of 100. Patients taking USTEKINUMAB who experience psoriasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIASIS is a less commonly reported adverse event for USTEKINUMAB, but still significant enough to appear in the safety profile.
In addition to psoriasis, the following adverse reactions have been reported for USTEKINUMAB:
The following drugs have also been linked to psoriasis in FDA adverse event reports:
PSORIASIS has been reported as an adverse event in 6,433 FDA reports for USTEKINUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIASIS accounts for approximately 1.9% of all adverse event reports for USTEKINUMAB, making it a notable side effect.
If you experience psoriasis while taking USTEKINUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.